Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Vivace Therapeutics to Unveil First Clinical Data for a Cancer Drug Targeting the Hippo Pathway
Details : VT3989 works by inhibiting the palmitoylation of members of the TEAD protein family, including both covalent and non-covalent inhibitors. It has shown its activity as a monotherapy against tumors that rely upon dysfunction of the hippo pathway.
Product Name : VT3989
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Boxer Capital
Deal Size : $30.0 million
Deal Type : Series C Financing
Details : Vivace Therapeutics’s compounds inhibit palmitoylation of members of the transcriptional enhanced associate domain (TEAD) protein family.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 16, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Boxer Capital
Deal Size : $30.0 million
Deal Type : Series C Financing
Lead Product(s) : VT-01
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ivy Brain Tumor Center
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The Ivy Brain Tumor Center, which employs a bold, early-phase clinical trials strategy, will evaluate Vivace’s novel development compound, VT-01, as an experimental therapy in two aggressive forms of brain cancer – glioblastoma and meningioma.
Product Name : VT-01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 26, 2020
Lead Product(s) : VT-01
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ivy Brain Tumor Center
Deal Size : Undisclosed
Deal Type : Collaboration